Similar articles

• Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service.

  Rodrigues IA, Reid HA, Ismail K, Amiel SA. Rodrigues IA, et al. Diabet Med. 2005 Jul;22(7):842-9. doi: 10.1111/j.1464-5491.2005.01539.x. Diabet Med. 2005. PMID: 15975097
• Consensus Statement on Use of Continuous Subcutaneous Insulin Infusion Therapy in the Hospital.

  Thompson B, Korytkowski M, Klonoff DC, Cook CB. Thompson B, et al. J Diabetes Sci Technol. 2018 Jul;12(4):880-889. doi: 10.1177/1932296818769933. Epub 2018 Apr 21. J Diabetes Sci Technol. 2018. PMID: 29681173 Free PMC article.
• Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes.

  Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK. Alemzadeh R, et al. Diabetes Technol Ther. 2005 Aug;7(4):587-96. doi: 10.1089/dia.2005.7.587. Diabetes Technol Ther. 2005. PMID: 16120030 Clinical Trial.
• A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.

  Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group. Weinzimer SA, et al. Diabetes Care. 2008 Feb;31(2):210-5. doi: 10.2337/dc07-1378. Epub 2007 Nov 5. Diabetes Care. 2008. PMID: 17989308 Clinical Trial.
• [The use of continuous subcutaneous insulin infusion (CSII) with personal insulin pumps in the treatment of children and adolescents with diabetes type 1].

  Jarosz-Chobot P. Jarosz-Chobot P. Wiad Lek. 2004;57(5-6):263-6. Wiad Lek. 2004. PMID: 15518073 Review. Polish.